Synairgen plc Issue of Equity (8916H)
March 15 2018 - 11:13AM
UK Regulatory
TIDMSNG
RNS Number : 8916H
Synairgen plc
15 March 2018
Synairgen plc
("Synairgen" or the "Company")
Issue of Equity
Southampton, UK - 15 March 2018: Synairgen (LSE: SNG), the
respiratory drug discovery and development company, following the
exercise of options by a former employee, has issued and allotted
70,205 new ordinary shares of 1 pence each in the Company
("Ordinary Shares"). Application has been made for the new Ordinary
Shares to be admitted to trading on AIM and dealings are expected
to commence on 29 March 2018.
The new Ordinary Shares will rank pari passu with the existing
shares of the Company. Following the exercise of options, the
Company's issued share capital consists of 91,432,817 Ordinary
Shares. Accordingly, the figure of 91,432,817 may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in the Company under the FCA's
Disclosure Guidance and Transparency Rules.
For further information please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
finnCap
Geoff Nash, James Thompson (Corporate Finance)
Stephen Norcross, Simon Johnson (Corporate Broking)
Tel: + 44 (0) 20 7220 0500
Consilium Strategic Communications (Financial Media and
Investor
Relations)
Mary-Jane Elliott / Sukaina Virji / Laura Thornton
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5701
About Synairgen
Synairgen is a respiratory drug discovery and development
company founded by University of Southampton Professors Stephen
Holgate, Donna Davies and Ratko Djukanovic. The business, focused
primarily on asthma and COPD, uses its differentiating human
biology BioBank platform and world-renowned international academic
KOL network to discover and develop novel therapies for respiratory
disease. Leveraging its scientific and clinical facilities at
Southampton General Hospital, the Company uses in vitro and ex vivo
models to progress opportunities into clinical development. The
BioBank of human samples is used in these models to increase
confidence in the likelihood of successful drug development. Core
to Synairgen's business strategy is the realisation of value via
licensing transactions. In August 2015 the Company entered into a
collaboration with Pharmaxis to develop an oral LOXL2 inhibitor to
reduce fibrosis in patients with idiopathic pulmonary fibrosis
(IPF). In December 2017 the collaboration agreement was amended as
Pharmaxis took on full responsibility for the programme, with
Synairgen receiving a GBP5 million upfront payment and circa 17% of
any future partnering proceeds from all fibrotic indications.
Synairgen is quoted on AIM (LSE: SNG). For more information about
Synairgen, please see www.synairgen.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEGGUGGWUPRGAA
(END) Dow Jones Newswires
March 15, 2018 11:13 ET (15:13 GMT)
Synairgen (LSE:SNG)
Historical Stock Chart
From Apr 2024 to May 2024
Synairgen (LSE:SNG)
Historical Stock Chart
From May 2023 to May 2024